FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry. Antibody to human CD52 is disclosed. Antibody is used for treatment or diagnostics of diseases associated with CD52+ cells, such as CLL and other leukemias, autoimmune diseases, organ transplant rejection, reaction “graft-versus-host” disease.
EFFECT: invention enables to bind CD52.
20 cl, 14 dwg, 2 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNOGLOBULINS K HUMAN CD52 | 2010 |
|
RU2603743C2 |
| ANTI-LIGAND 1 ANTIBODY OF PROGRAMMED CELL DEATH (PD-L1), ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL APPLICATION | 2016 |
|
RU2727914C2 |
| HUMANIZED ANTIBODIES TO CTLA4 | 2012 |
|
RU2629768C2 |
| ANTIBODY IGG WITH AFFINITY BINDING WITH RESPECT TO ANTIGENIC COMPLEX CD3, RECOMBINANT NUCLEIC ACIDS ENCODING ANTIBODY LIGHT AND HEAVY CHAIN, METHOD FOR PREPARING SYSTEM, METHOD FOR PREPARING ANTIBODY, METHOD FOR TREATMENT OF PATIENT | 1999 |
|
RU2244720C2 |
| HUMANISED ANTIBODIES SPECIFIC FOR HSP65-DERIVED PEPTIDE-6, METHODS AND USES THEREOF | 2010 |
|
RU2596925C2 |
| INTEGRIN β1 ANTIBODY COMPOSITIONS AND METHODS FOR USE THEREOF | 2013 |
|
RU2681994C2 |
| USING ANTI-TAU PS422 ANTIBODY FOR TREATING CEREBROPATHIES | 2010 |
|
RU2536247C2 |
| ANTI-c-Met ANTIBODY | 2009 |
|
RU2560257C2 |
| ANTIBODY AGAINST CLAUDIN 18A2 AND APPLICATION THEREOF | 2017 |
|
RU2793445C2 |
| MONOCLONAL PD-L1 ANTIBODY | 2017 |
|
RU2665790C1 |
